Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2017

Feb 01, 2018

SELL
$16.75 - $20.8 $1.07 Million - $1.33 Million
-64,030 Closed
0 $0
Q3 2017

Oct 23, 2017

BUY
$11.76 - $17.4 $33,339 - $49,328
2,835 Added 4.63%
64,030 $1.11 Million
Q2 2017

Aug 10, 2017

BUY
N/A
61,195
61,195 $785,000

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $8.49B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Nationwide Fund Advisors Portfolio

Follow Nationwide Fund Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nationwide Fund Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Nationwide Fund Advisors with notifications on news.